logo

Accurate cell signatures for the advancement of personalized medicine

Sector: Hospital • Location: Switzerland

Source: EU Funding & Tenders Portal

Project
Ended

Patient/individual specific cells, including induced pluripotent stem (iPS) cells will be crucial in defining tomorrow’s medicine owing to their uses in drug discovery, immunotherapy or cell therapy. These clinical applications require the utmost accurate and reliable identity and purity testing, however, the majority of cells stored worldwide fall short of a sufficient level of characterisation.

Status
Closed
Sector
Hospital
Location
Switzerland
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about Accurate cell signatures for the advancement of personalized medicine

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “Accurate cell signatures for the advancement of personalized medicine” is an infrastructure initiative in the Hospital sector, located in Switzerland. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Not available for this record.

Status

Original status

ended

Taiyo status

Closed

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

Patient/individual specific cells, including induced pluripotent stem (iPS) cells will be crucial in defining tomorrow’s medicine owing to their uses in drug discovery, immunotherapy or cell therapy. These clinical applications require the utmost accurate and reliable identity and purity testing, however, the majority of cells stored worldwide fall short of a sufficient level of characterisation. This project aims at validatating and commercializing an innovative method of diagnostic and quality control for human cells. It is based on our unprecedented ability to measure the expression of millions of uncharted RNA biomarkers called TEs, genetic units that contribute over 50% of the genome but that have been completely disregarded until very recently, mainly due to the challenge imposed by their complex analysis. Our new methodology provides a high-density barcode of cellular identity, opening the door for individual-specific cells to broad applications in biotechnology and medicine alike.

Location

Country

Switzerland

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Hospital

Article published date

2026-01-15

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project